Japanese stainless steel products manufacturer Nippon Kinzoku Co Ltd (TOKYO:5491) announced on Wednesday that it has begun mass production of ultra-thin, narrow-width stainless steel optimised for laser welding in ultra-fine insulin needles, establishing a stable supply system to meet growing global demand.
The company said demand for insulin needles is increasing alongside the global rise in diabetes and the adoption of ultra-fine needles designed to reduce pain and bruising. Growth in compact pen injectors and weight-management medications that use ultra-fine needles is also supporting market expansion.
Nippon Kinzoku supplies NK-304NKM, a specialised stainless steel for thin-walled welded tubes used in medical and cosmetic applications, offering stable weldability and drawability.
The industry is increasingly shifting from TIG or plasma welding to laser welding, enabling higher welding speeds and allowing base materials to be more than 50% thinner, including gauges of 0.08mm.
Following trials conducted with leading manufacturers in response to customer demand, Nippon Kinzoku has established mass-production capabilities for thin-walled, narrow-width materials designed to meet stringent quality and performance requirements.
DualityBio agrees global collaboration and licensing deal with Genentech
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease
AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Inify Laboratories launches UK operations with first NHS agreement
Senhwa completes enrolment in Phase 1b expansion trial of CX-5461
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
Revier Therapeutics closes EUR6m seed financing and launches operations
McKesson to acquire Precision Medicine Group for approximately USD2.25bn